Dr. Morimoto has over 25 years of industry experience in leading project teams in the development of innovative medicines, providing guidance in the design and execution of nonclinical, clinical and regulatory strategies with a therapeutic focus on CNS indications including Parkinson’s, Alzheimer’s and frontotemporal dementias. Previously, Bruce held leadership roles at Alto Neuroscience, Cerecin, Alkahest, Celerion and Allon Therapeutics.  He is currently consulting with several biotech companies helping to move their programs through clinical development and drug registration. Bruce started his career on the faculty in the Chemistry Department at Purdue University where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.